Edgewise Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops precision medicines for serious muscle diseases, including rare neuromuscular and cardiac conditions. The company operates a proprietary, muscle-focused drug discovery platform combining expertise in muscle biology and small molecule engineering to create sarcomere modulators and other targeted therapies; its lead product candidate is an oral myosin inhibitor for muscular dystrophies, while other clinical programs address hypertrophic cardiomyopathy and heart failure. Edgewise currently generates minimal revenue as it advances multiple candidates through clinical trials toward regulatory approval, with its future earnings dependent on successful FDA or foreign regulatory approvals and subsequent commercial adoption of approved medicines.